AssetMark Inc
CLDX icon

AssetMark Inc’s Celldex Therapeutics CLDX Stock Holding History

AssetMark Inc’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$781 Hold
21
– – ﹤0.01% 3194
2026
Q1 		$666 Buy
+21
New +$572 ﹤0.01% 3122
2024
Q4 		– Sell
-1
Closed -$34 – 2603
2024
Q3 		$34 Hold
1
– – ﹤0.01% 2229
2024
Q2 		$37 Buy
+1
New +$38 ﹤0.01% 2069

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's CLDX Position: Q2 2026 in Review

AssetMark Inc held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 21 shares worth $781. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

AssetMark Inc first reported a position in CLDX in Q2 2024 and has held it in 4 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • AssetMark Inc held 21 shares of Celldex Therapeutics worth $781 as of Q2 2026.
  • AssetMark Inc left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3194 holding.
  • AssetMark Inc first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.